# China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-Q
- Filed: 2021-08-13
- Accepted by EDGAR: Aug 13, 2021, 16:06 ET
- Period: 2021-06-30
- Accession: 0001213900-21-042474
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000121390021042474/f10q0621_chinapharmahold.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000121390021042474/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $2.4m | us-gaap:Revenues |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $4.8m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $2.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $4.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $71.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $343.7k | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $53.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $243.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$752.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-04-01 to 2021-06-30 | $72.4k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-01-01 to 2021-06-30 | $143.7k | us-gaap:InterestExpense |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$824.8k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | $399.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $15.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $1.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $5.3m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $19.9m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $12.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $13.4m | us-gaap:Liabilities |
| Long-term debt | at 2021-06-30 | $5.0m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2021-06-30 | $6.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 33,813 characters.

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as “anticipate,” “believe,” “expect,” “plan,” “intend,” “seek,” “estimate,” “project,” “could,” or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and Exchange Commission (the “SEC”). These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward-looking statements made in connection with this report that attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

### Business Overview & Recent Developments

We are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People’s Republic of China (the “PRC”). All of our operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.

China’s consistency evaluation of generic drugs had continued to proceed in the second quarter of 2021. The supporting policies from central and provincial governments have been constantly issued, including polices regarding consistency evaluation for injectable products. We have always taken the task of facilitating the consistency evaluation as our top priority, and worked on them actively. However, due to the continuous dynamic changes of the detailed policies, future market, expected investment, and return of investment (“ROI”) for each drug’s consistency evaluation, the whole industry, including us, has been making slow progress in terms of the consistency evaluation. We have a product that passed biological equivalents experiments of consistency evaluation in March 2021. We plan to submit application documents to NMPA in the near future.

We have taken a more cautious and flexible attitude towards the initiating and progressing of an existing product’s consistency evaluation and to cope with the changing macro environment of drug sales in China. On the one hand, since “4 + 7” (refers to 11 selected pilot cities, including 4 municipalities and 7 other cities) trial Centralized Procurement (“CP”) activities initiated in 2018, five rounds of CP activities had been carried out by June 2021, which significantly reduced the price of the drugs that won the bids. On the other hand, the consistency evaluation has been adopted as one of the qualification standards for participating in the CP activities. As a result, we need to balance at least the two factors above before making decisions for any products.

In addition, we continue to explore in the field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed according to the development of the times, social needs and changes in disease spectrum. According to the Outline of “Healthy China 2030” issued by Chinese government in October 2016, the total size of China’s health service industry will reach more than RMB 8 trillion by 2020 and RMB 16 trillion by 2030. This industry focuses on people’s daily life, aging and disease, pays attention to all kinds of risk factors and misunderstandings affecting health, and calls for self-health management, and advocates the comprehensive care of the entire process of life. It covers all kinds of health-related information, products and services, as well as actions taken by various organizations to meet the health needs. We launched Noni enzyme, a natural, Xeronine-rich antioxidant food supplement at the end of 2018, and wash-free sanitizer and masks in 2020 to address the market needs caused by COVID-19 in China. The impact of COVID-19 has continued. Masks and sanitizers have become long-time anti-epidemic materials. We have sufficient production capacity of medical masks, surgical masks and KN95 masks, which meets the personal needs for protection against the epidemic outbreak.

We will continue to optimize our product structure and actively respond to the current health needs of human beings.

### Market Trends

As a generic drug company we are presented with a huge domestic market. We believe that through further upgrades and consistency evaluations, we will be able to meet the European and American production standards, which will enable us to export our products to overseas markets. In the future, cost management and control ability will gradually become an important factor in determining the competitiveness of generic pharmaceutical enterprises. Although price control leads to a decline in the profitability, the winning enterprises in centralized procurement have a good chance of achieving price-for-volume in order to increase its market share and support its continuous innovation transformation. As a separate note, consumption upgrading in China drives the increase of optional consumption. With the improvement of residents’ quality of life, the healthcare demand is also changing. We believe that there are a large number of unmet demands in comprehensive healthcare and Internet healthcare sectors.

In addition, the Office of the State Council issued “*Pilot Plan for Marketing Authorization Holders”* on May 24, 2016, allowing eligible drug research and development institutions and scientific researchers to become Marketing Authorization Holders (“MAH”) by obtaining drug marketing authorization and drug approval numbers from the State Council. This policy uses a management model of separating drug marketing authorization and drug production licenses, thereby allowing an MAH to produce pharmaceuticals itself or to consign production to other pharmaceutical manufacturers. This policy not only transitions our production practices to meet the European and United States standards by separating drug approval and production qualifications, and therefore changing the existing model of bundling drug approval numbers to pharmaceutical manufacturers in China, but also serves as a supplement to the ongoing consistency evaluations policy.

In general, demand for pharmaceutical products is still experiencing steady growth in China. We believe the ongoing generic drug consistency evaluations and reform of China’s drug production registration and review policies will have major effects on the future development of our industry and may change its business patterns. We will continue to actively adapt to the national policy guidance and further evaluate market conditions for our existing products, and competition in the market in order to optimize our development strategy.

### Results of operations for the three months ended June 30, 2021

#### Revenue

Revenue decreased by 35.9% to $2.4 million for the three months ended June 30, 2021, as compared to $3.8 million for the three months ended June 30, 2020. This decrease was mainly due to a one-time foreign trade of COVID-19 testers that contributed approximately $1.7 million to our revenue in the second quarter of 2020, while we did not have similar kind of income in the quarter ended June 30, 2021.

Set forth below are our revenues by product category in millions (USD) for the three months ended June 30, 2021 and 2020, excluding the one-time revenue from the trading of COVID-19 testers during such period:

| Product Category | Three Months Ended June 30, 2021 | 2020 | Net% Change | Change |
| --- | ---: | ---: | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 0.89 | 0.57 | 0.32 | 56% |
| Anti-Viral/ Infection & Respiratory | 1.10 | 0.95 | 0.15 | 16% |
| Digestive Diseases | 0.09 | 0.10 | -0.01 | -10% |
| Other | 0.33 | 0.48 | -0.15 | -31% |
| Total | 2.41 | 2.10 | 0.31 | 15% |

The most significant revenue increase in terms of dollar amount was in our “CNS Cerebral & Cardio Vascular” product category which generated $0.89 million in the three months ended June 30, 2021, which represented an increase of $0.32 million as compared to $0.57 million in the three months ended June 30, 2020. This increase was mainly due to the increase in sales of Candesartan.

“Anti-Viral/ Infection & Respiratory” product category, generated $1.10 million in sales revenue in the three months ended June 30, 2021 compared to $0.95 million for the same period a year ago, which represented an increase of $0.15 million. This increase was mainly due to the sales of Cefaclor Dispersible Tablets.

“Others” product category generated $0.33 million in sales revenue in the three months ended June 30, 2021 compared to $0.48 million for the same period a year ago, which represented a decrease of $0.15 million. This decrease was mainly due to the decrease in sales of medical protection products. As COVID-19 has been effectively controlled in China during the quarter ended June 30, 2021, the demand for protective materials has dropped.

Our “Digestive Diseases” product category generated $0.09 million and $0.10 million in the three months ended June 30, 2021 and 2020, respectively.

| Product Category | Three Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 37% | 27% |
| Anti-Viral/ Infection & Respiratory | 45% | 45% |
| Digestive Diseases | 4% | 5% |
| Other | 14% | 23% |

For the three months ended June 30, 2021, revenue breakdown by product category showed a few changes to that of the same period in 2020. Sales of the “Anti-Viral/Infection & Respiratory” products category represented both 45% of total sales in the three months ended June 30, 2021 and 2020, respectively. The “CNS Cerebral & Cardio Vascular” product category represented 37% and 27% of total revenue in the three months ended June 30, 2021 and 2020, respectively. The “Digestive Diseases” product category represented 4% and 5% of total revenue in the three months ended June 30, 2021 and 2020, respectively. The “Other” product category represented 14% and 23% of revenues in the three months ended June 30, 2021 and 2020, respectively.

#### Cost of Revenue

For the three months ended June 30, 2021, our cost of revenue was $2.3 million, or 97% of total revenue, comparing to $2.6 million, or 70% of total revenue, for the same period in 2020. The decrease in cost of revenue was mainly due to the decrease in the sales price of some products that are part of a centralized procurement, and the increase in the price of some raw materials and overall packaging materials that meet the heightened environmental standards issued by the government. The increased percentage of cost to revenue was mainly due to (a) the impact of foreign trade of COVID-19 testers happened in the second quarter of 2020, which has a higher margin, and (b) impact of higher costs on pharmaceuticals.

#### Gross Profit and Gross Margin

Gross profit for the three months ended June 30, 2021 was $0.07 million, as compared to $1.15 million during the same period in 2020. Our gross profit margin in the three months ended June 30, 2021 was 2.9% as compared to 30.5% during the same period in 2020. The decrease in our gross profit margin was a result of the foreign trade of COVID-19 testers we completed in the second quarter of 2020, which has a higher margin; in addition, we had experienced selling price drop of some major products in this period.

#### Selling Expenses

Our selling expenses for the three months ended June 30, 2021 and 2020 were $0.4 million and $0.7 million, respectively. Selling expenses accounted for 18.4% of the total revenue in the three months ended June 30, 2021, as compared to 19.3% during the same period in 2020. Because of adjustments in our sales practices, and the reform of healthcare policies, we reduced number of personnel and expenses to efficiently support our sales and the collection of accounts receivable.

#### General and Administrative Expenses

Our general and administrative expenses were both $0.3 million for the three months ended June 30, 2021 and 2020, respectively. General and administrative expenses accounted for 13.7% and 8.6% of our total revenues in the three months ended June 30, 2021 and 2020, respectively.

#### Research and Development Expenses

Our research and development expenses for the three months ended June 30, 2021 were $0.05 million, as compared to $0.03 million in the same period in 2020. Research and development expenses accounted for 2.2% and 0.8% of our total revenues in the three months ended June 30, 2021 and 2020, respectively. These expenditures were mainly used for the consistency evaluations of our existing products.

#### Bad Debt Benefit

Our bad debt benefit for the three months ended June 30, 2021 was $4,744, as compared to $5,318 for the same period in 2020.

Our customers are primarily pharmaceutical distributors that sell our products to mostly government-backed hospitals. Therefore, the aging of our receivables from our customers tends to be longer-term.

The amount of accounts receivable that was past due (or the amount of accounts receivable that was more than 180 days old) was $0.07 million and $0.06 million as of June 30, 2021 and December 31, 2020, respectively.

The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of June 30, 2021 and December 31, 2020:

|  | June 30, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| 1 - 180 Days | 1.83% | 4.02% |
| 180 - 360 Days | 0.28% | 0.60% |
| 360 - 720 Days | 0.36% | 0.50% |
| \> 720 Days | 97.53% | 94.88% |
| Total | 100.00% | 100.00% |

19

Since the fourth quarter of 2018, our bad debt allowance estimate has been updated with a policy which requires no allowance of accounts receivable recognized that is within 180 days old, 10% of accounts receivable that is between 180 days and 365 days old, 70% of accounts receivable that is between 365 days and 720 days old, and 100% of accounts receivable that is greater than 720 days old. Prior to that, our policy was to recognize no allowance of accounts receivable that is within 90 days old, 10% of accounts receivable that is between 90 days and 365 days old, 70% of accounts receivable that is between 365 days and 720 days old, and 100% of accounts receivable that is greater than 720 days old.

We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and, when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $18.3 million as of June 30, 2021 and $18.2 million as of December 31, 2020. The changes in the allowances for doubtful accounts during the three months ended June 30, 2021 and 2020 were as follows:

|  | For the Three Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Balance, Beginning of Period | 18,013,339 | $17,334,819 |
| Bad debt expense (benefits) | (4,744) | (5,318) |
| Foreign currency translation adjustment | 308,395 | 12,596 |
| Balance, End of Period | 18,316,990 | $17,342,097 |

#### Income (Loss) from Operations

Our operating loss for the three months ended June 30, 2021 was $0.8 million, compared to an operating income of $0.07 million during the same period in 2020.

#### Net Interest Expense

Net interest expense for the three months ended June 30, 2021 was $0.07 million, as compared to $0.06 million in the same period in 2020.

#### Net Income (Loss)

Net loss for the three months ended June 30, 2021 was $0.8 million, as compared to net income of $0.01 million for the same period a year ago. The decrease in net income was mainly the result of a one-time foreign trade of COVID-19 testers we completed in the second quarter of 2020.

For the three months ended June 30, 2021, loss per basic and diluted common share was $0.02, as compared to earnings per basic and diluted common share was $0.00 for the three months ended June 30, 2020.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 45,579,557 for the three months ended June 30, 2021, and 43,579,557 for the three months ended June 30, 2020.

### Results of operations for the six months ended June 30, 2021

### Revenue

Revenue was $4.8 million and $5.5 million for the six months ended June 30, 2021 and 2020, respectively.

Set forth below are our revenues by product category in millions (USD) for the six months ended June 30, 2021 and 2020, respectively, excluding the one-time revenue from the trading of COVID-19 testers during such period:

| Product Category | Six Months Ended June 30, 2021 | 2020 | Net% Change | Change |
| --- | ---: | ---: | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 1.39 | 0.82 | 0.57 | 70% |
| Anti-Viral/ Infection & Respiratory | 2.59 | 2.14 | 0.45 | 21% |
| Digestive Diseases | 0.17 | 0.17 | 0.00 | 0% |
| Other | 0.62 | 0.70 | -0.08 | -11% |
| Total | 4.77 | 3.83 | 0.94 | 25% |

The most significant revenue increase in terms of dollar amount was in our “CNS Cerebral & Cardio Vascular”, which generated $1.39 million in sales revenue in the six months ended June 30, 2021 compared to $0.82 million in the same period a year ago, an increase of $0.57 million. This increase was mainly due to sales increase of Alginic Sodium Diester Injection.

Sales of our “Anti-Viral/ Infection & Respiratory” product category, which generated $2.59 million in sales revenue in the six months ended June 30, 2021 compared to $2.14 million in the same period a year ago, represented an increase of $0.45 million that was mainly caused by the increase in sales of Cefaclor Dispersible Tablets.

Sales of our “Digestive Diseases” product category generated $0.17 million in each of the six months ended June 30, 2021 and 2020, respectively.

Sales of “Other” product category generated $0.62 and $0.70 million in sales revenue in the six months ended June 30, 2021 and 2020, respectively. The decrease was mainly caused by the decrease in sales of masks.

| Product Category | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| CNS Cerebral & Cardio Vascular | 29% | 21% |
| Anti-Viral/ Infection & Respiratory | 54% | 56% |
| Digestive Diseases | 4% | 4% |
| Other | 13% | 18% |

For the six months ended June 30, 2021, revenue breakdown by product category remained similar to that of the same period in 2020. Sales of the “Anti-Viral/Infection & Respiratory” products category represented 54% and 56% of total sales in the six months ended June 30, 2021 and 2020, respectively. The “CNS Cerebral & Cardio Vascular” category represented 29% and 21% of total revenue in the six months ended June 30, 2021 and 2020, respectively. The “Digestive Diseases” category represented both 4% of total revenue in the six months ended June 30, 2021 and 2020. And the “Other” category represented 13% and 18% of revenues in the six months ended June 30, 2021 and 2020, respectively.

### Cost of Revenue

For the six months ended June 30, 2021, our cost of revenue was $4.4 million, or 93% of total revenue, comparing to $4.2 million, or 76% of total revenue, in the same period in 2020. The decrease in cost of revenue was mainly caused by a foreign trade of COVID-19 testers we completed in the second quarter of 2020. The increased percentage of cost to revenue was mainly due to (a) the impact of foreign trade of COVID-19 testers happened in the second quarter of 2020, which has a higher margin, and (b) impact of higher costs on pharmaceuticals.

### Gross Profit and Gross Margin

Gross profit for the six months ended June 30, 2021 was $0.3 million, compared to $1.3 million in the same period in 2020. Our gross profit margin in the six months ended June 30, 2021 was 7.2% compared to 24.3% in the same period in 2020. The decrease in our gross profit margin was mainly a result of a one-time foreign trade of COVID-19 testers we completed in the second quarter of 2020, which has a higher margin.; in addition, we had experienced selling price drop of some major products in this period. .

### Selling Expenses

Our selling expenses for the six months ended June 30, 2021 and 2020 were $0.8 million and $1.1 million, respectively. Selling expenses accounted for 17.3% of the total revenue in the six months ended June 30, 2021 compared to 19.0% in the same period in 2020.

### General and Administrative Expenses

Our general and administrative expenses for the six months ended June 30, 2021 were $0.74 million, which represented a decrease of $0.03 million compared to $0.71 million in the same period in 2020. Our general and administrative expenses accounted for 15.5% and 12.8% of our total revenues in the six months ended June 30, 2021 and 2020, respectively.

### Research and Development Expenses

Our research and development expenses for the six months ended June 30, 2021 and 2020 were $0.24 million and $0.08 million, respectively, representing an increase of $0.16 million compared to the same period of last year.

### Bad Debt (Benefit) Expenses

Our bad debt benefit was $0.01 million for the six months ended June 30, 2021, and bad debt expense was $0.02 million for the six months ended June 30, 2020.

The changes in the allowances for doubtful accounts during the six months ended June 30, 2021 and 2020 were as follows:

|  | For the Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Balance, Beginning of Period | $18,150,493 | $17,575,100 |
| Bad debt expense | (12,965) | 24,928 |
| Foreign currency translation adjustment | 179,462 | (257,931) |
| Balance, End of Period | $18,316,990 | $17,342,097 |

### Loss from Operations

Our operating loss for the six months ended June 30, 2021 was $1.5 million, compared to $0.5 million in the same period in 2020.

### Net Interest Expense

Net interest expense for the six months ended June 30, 2021 was $0.14 million, compared to $0.12 million for the same period in 2020.

### Net Loss

Net loss for the six months ended June 30, 2021 was $1.6 million, as compared to net loss of $0.6 million for the six months ended June 30, 2020. The decrease of net loss was mainly a result of a one-time foreign trade of COVID-19 testers we completed in the second quarter of 2020; while we did not have similar kind of income in this period.

For the six months ended June 30, 2021, loss per basic and diluted common share was $0.03, compared to loss per basic and diluted common share of $0.01 for the six months ended June 30, 2020.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 45,579,557 for the six months ended June 30, 2021, and 43,579,557 for the six months ended June 30, 2020.

### Liquidity and Capital Resources

Our principal source of liquidity is cash generated from operations, bank lines of credit and advances from our Chairperson, Chief Executive Officer and Interim Chief Financial Officer. We received advances from the CEO totaling $917,827 and repaid $251,861 of the advances during the six months ended June 30, 2021. Total amounts owed were $1,469,452 and $779,861 and are recorded as Borrowings from related parties on the accompanying condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, respectively.

Our cash and cash equivalents were $1.8 million, representing 8.9% of our total assets, as of June 30, 2021, as compared to $1.0 million, representing 4.5% of our total assets as of December 31, 2020. All of the $1.8 million of cash and cash equivalents as of June 30, 2021 are considered to be reinvested indefinitely in the Company’s Chinese subsidiary, Helpson and are not expected to be available for payment of dividends or for other payments to its parent company or to its shareholders.

In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 8,000,000 (approximately $1.2 million) have been advanced at December 31, 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit shall be repaid in installments semi-annually for two years from the date of the advance; the first repayment of RMB 500,000 (approximately $0.07 million) was made on October 20, 2020, the second repayment of RMB 300,000 (approximately $0.06 million) was made in January 2021, the third repayment of RMB 500,000 (approximately $0.08 million) was made in April 20, 2021, and the forth repayment of RMB 300,000 (approximately $ 0.05 million) was made in July 20, 2021. The Company has an additional RMB 2,000,000 (approximately $0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company.

On June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.3 million), all of which have been advanced. The loan bears interest at a rate of 4.05% per annum. The company has fully repaid this RMB 8,500,000 (approximately $1.3 million) on June 21, 2021 and on June 25, 2021, entered into a new loan agreement with Bank of Communications with a one year term, and an annual interest rate of 4.17%.

In addition, we entered into an eight-year construction loan facility on September 21, 2013. The total construction loan facility amount was RMB 80 million (approximately $13 million), which had been fully utilized through May 7, 2014. As of December 31, 2020, the construction loan installments to be repaid within the next 12 months are approximately $2.3 million. The total balance of the construction loan facility was RMB 14 million ($2.2 million) as of June 30, 2021, which is all due within 12 months. On July 10, 2021, we fully repaid such principal of RMB 80 million (approximately $12.4 million) of the construction loans per the payback schedule.

The Company also obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $344,098), and the remaining of RMB 856,660 (approximately $125,793) in October 2020 under this line. The loan bears interest at a rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance. These factors raised substantial doubts about the Company’s ability to continue as a going concern. Cash flow generated from operating activities, lines of credit and advances from our CEO were used to fund our daily operating expenses as well as the repayment of our loan facility.

Our net accounts receivable was $0.4 million and $0.5 million as of June 30, 2021 and December 31, 2020, respectively.

Total inventory was $3.0 million and $3.7 million as of June 30, 2021 and December 31, 2020, respectively.

Although the Company obtained lines of credit in April, June, and September 2020, there can be no assurance that the Company will be able to achieve its future strategic to accelerate the launch of nutrition products raising substantial doubt about its ability to continue as a going concern. Although our Chairperson and Chief Executive Officer had advanced funds for working capital during the first three months ended March 31, 2021, there can be no assurances that this will be the case in the future. We may seek debt or equity financing as necessary when we believe the market conditions are the most advantageous to us and/or reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

#### Operating Activities

Net cash provided by operating activities was $0.4 million in the six months ended June 30, 2021, as compared to net cash used by operating activities was $0.2 million for the same period in 2020.

Our net accounts receivable was $0.4 million and $0.5 million as of June 30, 2021 and December 31, 2020.

Total inventory was $3.0 million, as of June 30, 2021, and $3.7million as of December 31, 2020.

#### Investing Activities

During the six months ended June 30, 2021, net cash used in investing activities was $0.02 million as compared to $0.84 million for the six months ended June 30, 2020. The decrease was mainly due to the purchase of mask production lines in the same period in 2020.

Financing Activities

Cash flow generated by financing activities was $0.4 million in the six months ended June 30, 2021, as compared to $1.9 million in the six months ended June 30, 2020. The financing activities that occurred in the six months ended June 30, 2021 were primarily borrowing from related party.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies’ registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of June 30, 2021 and December 31, 2020, Helpson’s net assets totaled $4,437,000 and $5,777,000, respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson’s net assets that was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, was 50% of Helpson’s registered capital, which is $8,145,000 and $8,145,000 as of June 30, 2021 and December 31, 2020, respectively. The amount that Helpson must set aside for the statutory surplus fund accounts for 184% and 141% of its total net assets. There were no allocations to the statutory surplus reserve accounts during the six months ended June 30, 2021.

The Chinese government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires the submission of a payment application form together with certain invoices and executed contracts. The currency exchange control procedures imposed by Chinese government authorities may restrict the ability of Helpson, our Chinese subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

Off-Balance Sheet Arrangements

As of June 30, 2021, we did not have any off-balance sheet arrangements.

Critical Accounting Policies

Management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Our financial statements reflect the selection and application of accounting policies that require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, “Organization and Significant Accounting Policies”, is incorporated herein by reference.

## Market risk

As filed, 139 characters.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

## Controls and procedures

As filed, 2,566 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission (the “SEC”)’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2021 to satisfy the objectives for which they are intended. This was due to the material weakness in our internal control over financial reporting, with respect to our lack of accounting financial reporting personnel who were knowledgeable in U.S. GAAP, as disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 26, 2021. Notwithstanding the aforementioned material weakness, management has concluded that our consolidated financial statements included in this report are fairly stated in all material respects in accordance with U.S. GAAP for each period presented herein.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 13, 2021.
Source: SEC EDGAR, the filing index for accession 0001213900-21-042474. Last ingested by Listed: Nov 11, 2026, 00:23 ET. No prices; not investment advice.
